Nu-Med Plus (NUMD)

Overall impact
B (73)

Commentary

Nu-Med Plus is a strong overall performer. With a 'B' rating of 72.8 for overall impact (86th percentile compared to all companies), Nu-Med Plus ranks 21st out of 103 industry peers, behind MyMD Pharmaceuticals, electroCore, Endologix and 17 others, and ahead of Waters, Alphatec, Biolase and 79 others. On top material causes for Nu-Med Plus's industry (Healthcare Equipment), Nu-Med Plus performs well in Child and Maternal Health (83.8 score), Humane Treatment of Animals (91.0), Access to Affordable Healthcare (85.1) and 5 other causes where it received an 'A' score and performs poorly in Sanitation Access (38.5 score).
Impact
Cause NUMD
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Founded
2011
Employees
2
Sector
Health Care
Industry
Health Care Equipment & Supplies
Sub-industry
Health Care Supplies
SASB industry
Medical Equipment & Supplies
Headquarters
Ny, United States
Share classes
NUMD
Description
Nu-Med Plus, Inc., a medical device company, engages in the design, development, enhancement, and commercialization of medical devices worldwide. The company develops a nitric oxide generating formulation; a hospital bedside nitric oxide delivery system; a clinical unit for use in medical clinics and rehabilitation centers; a mobile rechargeable device to deliver nitric oxide gas; and a nitric oxide system that can be used for research applications, as well as a mobile/portable rechargeable device to deliver inhaled nitric oxide gas. The company was incorporated in 2011 and is based in Port Jefferson, New York.
Material causes
Ethos considers the following causes material for Nu-Med Plus, based on its industry sub-industry Health Care Supplies. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.